McSally opposes HR 3 to lower drug costs
McSally Opposes Bipartisan H.R. 3 Bill To Lower Prescription Drug Costs
PHOENIX — Today, U.S. Sen. Martha McSally once again declined to support H.R. 3, the bipartisan, U.S. House-passed bill that’s estimated to lower prescription drug costs, but which is opposed by a pharmaceutical industry-linked group that’s spent $1 million to support McSally’s 2020 campaign.
During a telephone town hall today, McSally was asked why she hasn’t come out in support of the bipartisan H.R. 3 plan to lower drug prices.
But rather than support the bipartisan bill, McSally instead talked about a bill that she announced over a week ago, but has yet to introduce, following expert criticism.
The only problem: Experts have looked at McSally’s alternative proposal and “see a number of ways in which her plan looks to be weaker” than H.R. 3, the bipartisan House plan.
“After tens of thousands of dollars in campaign checks from pharmaceutical corporations — and $1 million in TV ad support from a pharma-linked group — it’s no surprise that Senator McSally won’t take on big pharma and support H.R. 3 which will empower Medicare to negotiate lower drug prices on the most expensive drugs,” said Brad Bainum, Arizona Democratic Party spokesperson.